SCHEMBL2434906

SCHEMBL2434906

O=C(O)c1ccc(-n2cc(-c3ccnc4[nH]ccc34)cn2)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 5/20 0.74
AURKB Q96GD4 3/20 0.56
AURKA O14965 2/20 0.56
INCENP Q9NQS7 2/20 0.56
TPX2 Q9ULW0 2/20 0.56
IKBKB O14920 2/20 0.53
CHUK O15111 2/20 0.53
NEK1 Q96PY6 1/20 0.48
NUDT1 P36639 2/20 0.48
JAK2 O60674 4/20 0.48
JAK3 P52333 3/20 0.48
DAPK3 O43293 1/20 0.48
PRKD3 O94806 1/20 0.48
MAP4K4 O95819 1/20 0.48
PAK4 O96013 1/20 0.48
CSF1R P07333 1/20 0.48
RET P07949 1/20 0.48
IGF1R P08069 1/20 0.48
FGFR1 P11362 1/20 0.48
PRKACA P17612 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL100305 0.86 GRM4 (1.00) GRM4AURKBAURKAINCENPTPX2
SCHEMBL100615 0.84 GRM4 (0.62) GRM4AURKBAURKAINCENPTPX2
Trifluoroacetic Acid SCHEMBL4092717 0.84 GRM4 (0.81) GRM4AURKBAURKAINCENPTPX2
SCHEMBL2436937 0.81 GRM4 (0.61) GRM4AURKBAURKAINCENPTPX2
SCHEMBL4791827 0.81 IKBKB (0.76) AURKBAURKAINCENPTPX2IKBKB
Trifluoroacetic Acid SCHEMBL4082643 0.81 GRM4 (0.57) GRM4AURKBAURKAINCENPTPX2
SCHEMBL6123302 0.81 GRM4 (0.77) GRM4AURKBAURKAINCENPTPX2
Trifluoroacetic Acid SCHEMBL4096450 0.81 GRM4 (0.62) GRM4AURKBAURKAINCENPTPX2
SCHEMBL103032 0.81 GRM4 (0.72) GRM4AURKBAURKAINCENPTPX2
SCHEMBL2710540 0.79 GRM4 (0.77) GRM4HTR2BMTNR1AKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2343299-B9 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors INCYTE HOLDINGS CORP (US) 2017-03-08 EP claimed
EP-2348023-B9 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors INCYTE HOLDINGS CORP (US) 2017-03-08 EP claimed
EP-2343299-B1 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors INCYTE CORP (US) 2015-11-04 EP claimed
EP-2348023-B1 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors INCYTE CORP (US) 2015-05-06 EP claimed
EP-1966202-B1 HETEROARYL SUBSTITUTED PYRROLO[2,3-B]PYRIDINES AND PYRROLO[2,3-B]PYRIMIDINES AS JANUS KINASE INHIBITORS INCYTE CORP (US) 2011-09-21 EP claimed
WO-2013173506-A2 METHOD OF TREATING MUSCULAR DEGRADATION RIGEL PHARMACEUTICALS, INC. (US) 2013-11-21 WO disclosed